| Human Melanoma DNA Methylation PCR Array, Signature Panel: EAHS-081Z |
| The Human Melanoma EpiTect Methyl II Signature PCR Array profiles the promoter methylation status of a panel of 22 genes showing hypo- or hypermethylation in melanoma. Melanoma accounts for less than 5% of skin cancers, but 80% of the deaths, illustrating the aggressiveness and malignancy of the disease. Epigenetic studies of dysregulated and hypermethylated tumor suppressor genes have identified novel therapeutic targets for melanoma. This array includes genes frequently observed by genomewide analyses to be hypermethylated in melanoma, as well as genes involved in melanoma onset and progression. Profiling cellular or fresh tissue genomic DNA samples with these arrays may help correlate CpG island methylation status with biological phenotypes. The results may also help provide further insights into the molecular mechanisms and biological pathways behind oncogenesis and cancer biology. With a simple restriction enzyme digestion and real-time PCR, research studies can analyze the promoter methylation status of 22 different genes involved in melanoma initiation and progression with this DNA methylation PCR array.
The EpiTect Methyl II PCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
The EpiTect Methyl II PCR Arrays use the MethylScreen™ Technology provided under license from Orion Genomics, LLC |
|
Signaling Pathways Dysregulated in Melanoma: GDF15 (PLAB), RB1.
Cellular Stress Responses:
Drug & Chemical Response: CDH3, DNAJC15, LRP2, SOCS3.
Immune: DPP4, IRF8, PRDX2, THBD.
Hypoxia: AKAP12, DPP4, SOCS3.
Oxidative: PRDX2, TPM1.
Cell Growth & Proliferation: AKAP12, DPP4, LRP2, PPP2R4, PRDX2, RB1, SOCS2.
Extracellular Matrix & Cell Adhesion: ADAMTS18, CDH3, DPP4, ENC1, MME, QPCT, SOCS2, SOCS3, TPM1.
Apoptosis Regulation: PRDX2, SOCS2, SOCS3, TNFRSF10A, TP53INP1.
Transcription Factors & Cofactors: IRF8, RB1, TNFRSF10A.
Others: PPP1R3C, RASEF |
